ELSEVIER
SAUNDERS

CLINICS
IN CHEST
MEDICINE

Clin Chest Med 26 (2005) 721–739

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

ACE. See *Angiotensin-converting enzyme (ACE).*

Acinetobacter sp.
  A. baumannii, VAP due to, 89–90
  VAP due to, mechanisms of resistance of, 76–77

Acremonium sp., in transplant recipients, 676, 677

Acute high-altitude pulmonary illness, in sojourners, 396–397

Acute lung injury (ALI), **105–112**
  altered immunity during, 106–107
  bacterial superinfection in animals with, 105–106

Acute lung injury, after HSCT, **561–569.** See also *Hematopoietic stem cell transplantation (HSCT), acute lung injury after.*

Acute mountain sickness, features of, 397

Acute respiratory distress syndrome (ARDS), VAP during, clinical studies of, 140

Acute respiratory failure, after transplantation, 623–624

Adaptive immunity, pneumonia in SOT recipients and, 114

Adenovirus, in transplant recipients, 714–715

Aerobic fitness, in divers, 489

Aerobic gram-negative pneumonia, CAP due to, 50

Aerobic gram-positive cocci, VAP due to, 91–92

Aerosol(s), inhaled, in microgravity studies, 432

Aerospace exposures, pulmonary function effects of, 492–493

Age
  advanced, as factor in delayed resolution of pneumonia, 147
  as factor in tuberculosis, 186

Aging, effects on respiratory system, **469–483.** See also *Respiratory system, aging effects on.*

Air travel, pulmonary function effects of, 493–499

Airspace consolidation
  after transplantation, 546–551
  defined, 546

Airway(s)
  artificial, colonization of, in pneumonia, 41–42
  extra-thoracic, limitations of, respiratory response to exercise and, 446–448
  intra-thoracic, limitations of, respiratory system response to exercise and, 448–453
  limitations of, exercise and, 453–454
  lower, colonization of, in pneumonia, 41
  peripheral, age-associated changes in, 472
  upper, injury of, after HSCT, 561

Airway resistance and conductance, in older persons, 476

ALI. See *Acute lung injury (ALI).*

Allograft rejection, after lung transplantation, **599–612.** See also *Lung transplantation, allograft rejection after.*

Altitude
  high
    drive to breathe at, 406
    respiration at, limits of, **405–414.** See also *High-altitude environment.*
  pulmonary effects of, 491
  terrestrial, pulmonary function effects of, 499–503

Alveolar ventilation, EIAH and, 463

Aminoglycoside(s), for active tuberculosis, 277

Amphotericin B, for *Aspergillus* pulmonary infections in transplant recipients, 667

Amplification, phage, in pulmonary tuberculosis diagnosis, 261–262

Anaerobe(s), VAP due to, 93

Anaerobic bacterial pneumonia, CAP due to, 50

0272-5231/05/$ – see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/S0272-5231(05)00102-4

Anastomosis(es), after lung transplantation, 616–617

Angiotensin-converting enzyme (ACE), in genetic susceptibility to pneumonia, 34

Anti–B-cell antibodies, for PTLD, 640

Antibiotic(s). See *Antimicrobial(s).*

Antibody(ies), anti–B-cell, for PTLD, 640

Antigen recognition pathways, in genetic susceptibility to pneumonia, 30–31

Anti-inflammatory cytokines, in genetic susceptibility to pneumonia, 33–34

Anti-inflammatory therapy, in systemic response to pneumonia, 4–5

Antimicrobial(s)
for CAP, **65–73.** See also *Community-acquired pneumonia (CAP), treatment of, antimicrobial.*
for hospital-acquired pneumonia, **97–104.** See also *Hospital-acquired pneumonia, treatment of, antimicrobial.*
in hospital-acquired pneumonia prevention, 138–139
in pneumonia resolution, 148–149

Antimycobacterial agents, for active tuberculosis, 274–277

Antiretroviral therapy, with tuberculosis treatment, challenges of, 286–292

Antiviral agents, for PTLD, 638

Apnea diving
cardiovascular effects of, 389–391
changes in partial pressure of breathing gases during descent and ascent, 385–387
decompression sickness due to, 387–389
described, 381–382
excessive hyperventilation during, 387
nitrogen narcosis due to, 387–389
physiological and clinical aspects of, **381–394**

ARDS. See *Acute respiratory distress syndrome (ARDS).*

Artificial airways, colonization of, in pneumonia, 41–42

Aspergillus pulmonary infections, in transplant recipients, **661–674**
clinical presentation of, 663–665
diagnosis of, 665–667
epidemiology of, 662–663
host defense, 661–662
management of, 667–668
organism description, 661
prevention of, 668–669

Aspergillus sp., described, 661

Aspiration
gastric, in pneumonia, 40
oropharyngeal, in pneumonia, 40

Asthma
after HSCT, 572
at terrestrial altitude, 501
exercise effects on, 448–450
in divers, 490

B

Bacille Calmette-Guerin vaccination, effect on tuberculin skin test, 306

Bacillus(i), gram-negative, in pneumonia resolution, 146

Bacteria
gram-negative, nonfermentative, VAP due to, 87–90
VAP due to, mechanisms of resistance of, **75–79.** See also *Ventilator-associated pneumonia (VAP), bacteria causing, mechanisms of resistance of.*

Bacterial infection, ALI and, **105–112**

Bacterial pneumonia
HIV/AIDS and, 51–52
in transplant recipients, **647–659.** See also *Solid organ transplant recipients, bacterial and mycobacterial pneumonia in.*

Barotrauma, pulmonary, diving while breathing compressed gas and, 358–363

Beta-lactam resistance, CAP due to, 58–59

Blastomyces dermatitidis, in transplant recipients, 676, 679–680

Blastoschizomyces sp., in transplant recipients, 676, 681

Breath-hold diving. See *Apnea diving.*

Breathing
at depth, **355–380.** See also *Diving, while breathing compressed gas.*
regulation of, in older persons, 477–478
sleep-disordered, at terrestrial altitude, 500
work of
at high altitude, 407–410

during exercise, minimization of, in healthy untrained normal subjects, 440

Breathing gases, partial pressure of, changes in, during apnea diving, 385–387

Bronchiolitis obliterans, after HSCT, 572–576

Bronchiolitis obliterans organizing pneumonia, after HSCT, 576–577

Bronchiolitis obliterans syndrome
allograft rejection and, 606–608
in lung transplant recipients, pneumonia with, 649

Bronchoscopy, fiberoptic, in pulmonary tuberculosis diagnosis, 256–257

C

Cancer, lung, after lung transplantation, 618

CAP. See *Community-acquired pneumonia (CAP).*

Carbon monoxide transfer factor, in older persons, 477

Cardiac output
in microgravity studies, 423–424
increased, in healthy untrained normal subjects, 441

Cardiovascular disease
at terrestrial altitude, 501–502
in divers, 491

Cardiovascular system, apnea diving effects on, 389–391

CARVs. See *Community-acquired respiratory viruses (CARVs).*

Caspofungin, for *Aspergillus* pulmonary infections in transplant recipients, 667–668

CDI4, in genetic susceptibility to pneumonia, 30–31

Cellular immunotherapy, for PTLD, 640–641

Chemotherapy
cytotoxic, for PTLD, 639–640
for active tuberculosis, axioms of, 273–274
standardized short-course, in DOTS strategy for controlling global tuberculosis epidemic, 198–199

Chest wall
age-associated changes in, 469
shape and movement of, in microgravity studies, 420

Chest wall mechanics, lung volumes and, 417–420

CHF. See *Congestive heart failure (CHF).*

Children
latent *Mycobacterium tuberculosis* infection in, treatment of, 322
tuberculosis in, **295–312**
diagnosis of, smear for acid-fast bacilli and mycobacterial culture, 306
epidemiology of, 295–297
extrapulmonary, 300–302
in newborns, 302–303
latent
clinical and radiographic manifestations of, 299–303
diagnosis of, 303–306
infectious, 299
risk factors for, 297–298
treatment of, 306–309
pathogenesis of, 298–299
prevalence of, 295
public health aspects of, 309–310
pulmonary, 299–300
tuberculous disease, 299

Chlamydia sp.
C. pneumoniae, CAP due to, 51
in pneumonia resolution, 146

Chronic lung disease, after HSCT, **571–586.** See also *Hematopoietic stem cell transplantation (HSCT), chronic lung disease after.*

Chronic mountain sickness, 396

Chronic obstructive pulmonary disease (COPD), at terrestrial altitude, 500–501

CMV pneumonia. See *Cytomegalovirus (CMV) pneumonia.*

Coagulation system genes, in genetic susceptibility to pneumonia, 34–35

Coccidioides immitis, in transplant recipients, 676, 680

Coccus(i), gram-negative, aerobic, VAP due to, 91–92

Community-acquired pneumonia
in HSCT recipients, 654–655
in solid organ transplant recipients, 648–649

Community-acquired pneumonia (CAP)
beta-lactam resistance and, 58–59
causes of, **47–55**
aerobic gram-negative pneumonia, 50
anaerobic bacterial pneumonia, 50

atypical pathogens in, 50–51
Chlamydia pneumoniae, 51
Haemophilus influenzae, 48–49
HIV/AIDS, 51–53. See also *HIV/AIDS*.
pathogens in, 53
Legionella pneumophila, 51
miscellaneous, 51, 52
Moraxella catarrhalis, 49–50
Mycoplasma pneumoniae, 50–51
Staphylococcus aureus, 50
Streptococcus pneumoniae, 47–48
typical pathogens in, 47–50
criteria for hospital and ICU admission, 66–67
defined, 65
epidemiology of, 65–66
fluoroquinolone resistance and, 59–60
clinical significance of, 60
macrolide resistance and, 59
clinical significance of, 60
penicillin resistance and, clinical significance of, 60
prevalence of, 57
PRSP, 57
resolution of, 144
sepsis due to, **19–28**
epidemiology of, 20–21
mortality related to, risk factors for, 21–22
pathophysiology of, 22–24
treatment of, 24–27
corticosteroids in, 25–26
drotrecogin alfa in, 24–25
early goal-directed therapy in, 26–27
insulin therapy in, 26
severity of, assessment of, 66–67
treatment of, 61–63
antimicrobials in, **65–73**
described, 67–69
duration of, 69–70

Community-acquired respiratory virus (CARV), 707
prevention of, 716–718

Compressed gas, diving while breathing, **355–380.** See also *Diving, while breathing compressed gas.*

Congestive heart failure (CHF), at terrestrial altitude, 502

COPD. See *Chronic obstructive pulmonary disease (COPD).*

Coronary artery disease, at terrestrial altitude, 501–502

Coronavirus, in transplant recipients, 715–716

Corticosteroid(s), for CAP-related sepsis, 25–26

Cryptococcus sp., in transplant recipients, 676, 680–681

Culture(s), in pulmonary tuberculosis diagnosis, 257–258

Cystic fibrosis, at terrestrial altitude, 501

Cytokine(s)
anti-inflammatory, in genetic susceptibility to pneumonia, 33–34
for PTLD, 639
proinflammatory, in genetic susceptibility to pneumonia, 31–33

Cytomegalovirus (CMV), prevention of, 698–700

Cytomegalovirus (CMV) pneumonia, in transplant recipients, **691–705**
agents with activity against, 697–698
clinical syndromes of, 695–697
diagnosis of, 693–695
epidemiology of, 695–697
heart, 697
heart-lung, 696–697
HSCT, 695–696
liver, 697
lung, 696
pathogenesis of, 691–693
prevention of, 698–700
renal, 697
resistance against, 700–701
treatment of, 700
virology of, 691–693

Cytotoxic chemotherapy, for PTLD, 639–640

D

Decompression illness
diving while breathing compressed gas and, 363–368
prior, in divers, 491

Decompression sickness, apnea diving and, 387–389

Decompression stress, effects on lung function during diving, 357

Deep venous thrombosis, at high altitude, 499

De-escalation, antimicrobials for hospital-acquired pneumonia and, 101

Delayed pulmonary toxicity syndrome, after HSCT, 577–578

Dematiaceous Hymomycetes, in transplant recipients, 676, 678–679

Diaphragmatic dysfunction, after transplantation, 624–625

Diaphragmatic hernia, after transplantation, 625

Diarylquinolones (R207910), for tuberculosis, 333

Diffuse alveolar hemorrhage, after HSCT, 564–565

Diffusing capacity, lung water and, in microgravity studies, 425

Diffusion limitation, EIAH and, 462

Dihydroimidazo-oxazoles (OPC-67683), for tuberculosis, 335

1,25-Dihydroxyvitamin D_3, in genetic susceptibility to tuberculosis, 238

Directly observed treatment, short course (DOTS) strategy, for controlling global tuberculosis epidemic, **197–205**
  administrative commitment to, 197
  drug quality in, 199
  for multi-drug resistant TB, 200–201
  HIV infection and, 201–202
  political commitment to, 197
  results of, 200
  sputum microscopy of patients attending health facilities, 198
  standardized short-course chemotherapy, 198–199
  systemic monitoring and accountability, 200

Dive(s), single, respiratory effects of, 358

Diving
  aerobic fitness in, 489
  apnea, physiological and clinical aspects of, **381–394**
  asthma and, 490
  breath-hold. See *Apnea diving.*
  cardiovascular disease and, 491
  depth of, theoretic limits of, 382–385
  fitness for
    concomitant respiratory diseases and, 369–372
    respiratory assessment of, 371–372
  hazards of, 486–488
  lung function during
    decompression stress and, 357
    diving exposure and, 356
    gas density and, 357–358
    hyperoxia and, 356–357
    physical and physiological factors affecting, 356–358
    respiratory heat and water loss and, 358
    respiratory mechanical loading and, 357–358
  methods of, 355–356
  patent foramen ovale and, 491
  pneumothorax and, 490
  prior decompression illness and, 491
  pulmonary function effects of, 486–491
    described, 488–489
    long-term, 372–373
  routine evaluation of candidates for, 489
  smoking and, 490
  while breathing compressed gas, **355–380**
    clinical problems related to, 358–369
    decompression illness due to, 363–368
    fitness to dive effects on concomitant respiratory diseases, 369–372
    pulmonary barotrauma due to, 358–363
    pulmonary edema due to, 368–369
  with respiratory diseases, 370–371

DOTS. See *Directly observed treatment, short course (DOTS) strategy.*

Drotrecogin alfa, for CAP-related sepsis, 24–25

Drug(s)
  for *Aspergillus* pulmonary infections in transplant recipients, 667–668
  for tuberculosis, **327–340**
    new agents. See also specific drug and *Tuberculosis, treatment of, drugs in.*
  tuberculosis resistant to, 175–176

Drug resistance
  in pulmonary tuberculosis diagnosis, rapid detection of, 261–262
  tuberculosis effects of, transmission- and pathogenesis-related, 222

Drug toxicity, after transplantation, 627
  lung, 618–619

E

Edema, pulmonary
  diving while breathing compressed gas and, 368–369
  interstitial, 463–464

Effector mechanisms, in genetic susceptibility to pneumonia, 34–35

Effusion(s), pleural, after transplantation, 625

EIAH. See *Exercise-induced arterial hypoxemia (EIAH).*

Endemic mycoses, in transplant recipients, 676, 679–680

Energetic(s), in high-altitude environment, 407–410

Enterobacter cloacae, VAP due to, mechanisms of resistance of, 77–78

Enterobacteriaceae, VAP due to, 90

Environment(s)
extreme, pulmonary function in, **485–507.** See also *Extreme environments, pulmonary function effects of.*
high-altitude. See *High-altitude environment.*
hyperbaric, pulmonary function effects of, 486–491
hypobaric, pulmonary function effects of, 491
space, 415–417

Environmental factors, lung infection due to, 13–16

Enzyme(s), ACE, in genetic susceptibility to pneumonia, 34

Ethambutol, for active tuberculosis, 276

Ethnicity, as factor in tuberculosis, 186

Exercise
effects on asthma, 448–450
extra-thoracic obstruction due to, 446–448
in high-altitude pulmonary edema–prone persons, pulmonary vascular response to, 445–446
in microgravity studies, 429
in persons with intrapulmonary arteriovenous shunting, 444–445
limitations with, after lung transplantation, 619
maximal, lung at, **459–468**
pulmonary capillary stress failure due to, 465
respiratory system response to, **439–457**
asthma, 448–450
extra-thoracic airway limitations of, 446–448
in healthy untrained normal subjects, 439–441
exercise hyperventilation, 439–440
increased cardiac output, 441
maximizing gas exchange efficiency, 440–441
minimization of work of breathing, 440
shunting, 441–444
intra-thoracic airway limitations, 448–453
pulmonary vascular and airway limitations, 453–454
pulmonary vascular limitations, 441–446
responses to, pulmonary function and, 460
ventilation and, in older persons, 478
ventilatory response to, in older persons, 478–479

Exercise hyperventilation, in healthy untrained normal subjects, 439–440

Exercise testing, at high altitude, 498

Exercise training, response to, in older persons, 478

Exercise-induced arterial hypoxemia (EIAH), 460–463
alveolar ventilation and, 463
described, 460–462
diffusion limitation and, 462
mechanisms of, 462
shunts and, 462
ventilation-perfusion ratio inequality and, 462

Exercise-induced pulmonary hemorrhage, 464–465

Experimental lung injury, infection and, 105–106

Extra-thoracic airway, limitations of, respiratory system response to exercise and, 446–448

Extravehicular activity, in microgravity studies, 433–434

Extreme environments
pulmonary function effects of
aerospace exposures, 492–493
air travel, 493–499
altitude, 491
hyperbaric, 486–491. See also *Diving.*
hypobaric, 491
terrestrial altitude, 499–503

F

Fiberoptic bronchoscopy, in pulmonary tuberculosis diagnosis, 256–257

Fingerprinting patterns, in *Mycobacterium tuberculosis* complex study, 208

Flow-volume curves, in older persons, 475–476

Fluoroquinolone(s)
for active tuberculosis, 276–277
resistance to, CAP due to, 59–60
clinical significance of, 60

Functional residual capacity, in microgravity studies, 417–418

Fungal pneumonia
factors predisposing to, 675
HIV/AIDS and, 53
non-*Aspergillus,* in transplant recipients, **1–16**
Blastomyces dermatitidis, 676, 679–680
Blastoschizomyces sp., 676, 681
Coccidioides immitis, 676, 680
Cryptococcus sp., 676, 680–681
dematiaceous Hymomycetes, 676, 678–679
diagnosis of, 681–682
endemic mycoses, 676, 679–680
Histoplasma capsulatum, 676, 679

hyaline Hyphomyetes, 676–678
Paracoccidioides brasiliensis, 676, 680
Penicillum marneffei, 676, 680
Pneumocystis pneumonia, 676, 681
treatment of, 682–685
Trichosporon sp., 676, 681
yeasts, 676, 680–681
zygomycetes, 678

Fungus(i)
hyaline Hyphomyetes, 676–678
non-*Aspergillus*, types of, 675–681

Fusarium sp., in transplant recipients, 676

G

Gas(es)
breathing, changes in partial pressure of, during apnea diving, 385–387
compressed, diving while breathing, **355–380.** See also *Diving, while breathing compressed gas.*

Gas density, effects on lung function during diving, 357–358

Gas exchange
in lung, in high-altitude environment, limitations of, 410–413
in older persons, 476–477

Gastric aspiration, in pneumonia, 40

Gastric colonization, in pneumonia, 40

Gene(s), coagulation system, in genetic susceptibility to pneumonia, 34–35

Genetic(s)
in high-altitude–related pulmonary disease, 399–401
in pneumonia, **29–38.** See also *Pneumonia(s), genetic susceptibility to.*

Genetic susceptibility, to tuberculosis, **233–246.** See also *Tuberculosis, genetic susceptibility to.*

Genome(s), sequenced, in *Mycobacterium tuberculosis* complex study, 208

Global Alliance for Tuberculosis Drug Development, **341–347**
described, 341–342
future directions for, 346
global product development public–private partnerships, 346
strategy of, 342–345

Global product development public–private partnerships, in Global Alliance for Tuberculosis Drug Development, 345–346

Gram-negative bacilli, in pneumonia resolution, 146

Gram-negative bacteria, nonfermentative, VAP due to, 87–90

Gram-positive cocci, aerobic, VAP due to, 91–92

Ground-glass opacity
after transplantation, 551–552
defined, 551

H

Haemophilus sp.
H. influenzae
CAP due to, 48–49
VAP due to, 90–91
in pneumonia resolution, 145

Heart transplantation, 529–532
allocation system for, 530–531
CMV infections after, 697
contraindications for, 529–530
indications for, 529–530
noninfectious pulmonary complications of, **623–629**
outcomes of, 531–532
pretransplantation care, 531
status in U.S., 529
surgical techniques, 531

Heart-lung transplantation, CMV infections after, 696–697

Heat shock proteins, in genetic susceptibility to pneumonia, 33

Hematopoietic stem cell transplant (HSCT) recipients
CMV infections in, 695–696
community-acquired pneumonia in, 654–655
hospital-acquired pneumonia in, 654–655
infections in, 654–656
mycobacterial infections in, 656
Nocardia infections in, 655
nontuberculous mycobacteria in, 656
PTLD in, 636–638
tuberculosis in, 656

Hematopoietic stem cell transplantation (HSCT)
acute lung injury after, **561–569**
clinical approach to, 565–566
diffuse alveolar hemorrhage, 564–565
idiopathic pneumonia syndrome, 561–563
intensive care for, outcomes of, 566

periengraftment respiratory distress syndrome, 563–564
radiation pneumonitis, 561
upper airway injury, 561
Aspergillus pulmonary infections after, 662–663
chronic lung disease after, **571–586**
asthma, 572
bronchiolitis obliterans, 572–576
bronchiolitis obliterans organizing pneumonia, 576–577
delayed pulmonary toxicity syndrome, 577–578
pulmonary complications, 580
pulmonary cytolytic thrombi, 578–579
pulmonary function abnormalities, 571–572
pulmonary veno-occlusive disease, 579–580
donor selection for, 518–520
future directions in, 525
historical background of, 517–518
immunologic reconstitution after, 522–524
indications for, 517–518
mechanism of injury in, 520–521
outcomes of, 524–525
overview of, **517–527**
preparative regimens for, 518–520
stem cell source for, 518–520
upper airway injury after, 561

Hemorrhage
diffuse alveolar, after HSCT, 564–565
pulmonary, exercise-induced, 464–465

Hepatopulmonary syndrome, **587–591**
clinical presentation of, 587
diagnostic criteria for, 587–588
liver transplantation for
clinical course after, 590–591
intraoperative concerns, 590
survival after, 590–591
monitoring of, before liver transplantation, 589
natural history of, 589
pathophysiology of, 589
screening for, 588–589
special considerations in, before liver transplantation, 589
treatment of, before liver transplantation, 589

Hernia(s), diaphragmatic, after transplantation, 625

Herpes viruses, in transplant recipients, 715–716

High-altitude environment, **405–414**
described, 405–406
drive to breathe in, 406
energetics in, 407–410
gas exchange in lung in, limitations of, 410–413
ventilatory demand at, 406–407
work of breathing at, 407–410

High-altitude pulmonary edema–prone persons, exercise in, pulmonary vascular response to, 445–446

High-altitude–related pulmonary disease, **395–404**
demographics of, 396, 398
described, 395
epidemiology of, 396–398
genetics in, 399–401
in inbred populations, 400
risk factors for, 398–401

High-altitude–related pulmonary edema, features of, 397–398

Histoplasma capsulatum, in transplant recipients, 676, 679

HIV. See *Human immunodeficiency virus (HIV) infection.*

HIV/AIDS
bacterial pneumonia with, 51–52
CAP due to, 51–53
pathogens in, 53
fungal pneumonia with, 53
mycobacterial pneumonia with, 52–53

HLA-DR2, in genetic susceptibility to tuberculosis, 238

Hospital-acquired pneumonia
factors predisposing to, 12–16
host-related, 12–13
in HSCT recipients, 654–655
in solid organ transplant recipients, 648
prevention of, **135–142**
antibiotics in, 138–139
appropriate staffing levels in ICU in, 136
avoidance of large gastric volumes in, 137
avoidance of RBC transfusions in, 139
biofilms in, 137–138
decolonization of aerodigestive tract in, 138
disinfection in, 138
hand washing in, 138
implementation of, barriers to, 139–140
NIPPV in, 135
nonpharmacologic approaches in, 135–138
oral intubation in, 136–137
pharmacologic approaches to, 138–139
semi-erect positioning in, 137
shortening mechanical ventilation time in, 135–136
subglottic suctioning in, 136
tracheal intubation avoidance in, 135

vaccines in, 139
ventilator circuit in, 137
treatment of, antimicrobials in, **97–104**
de-escalation and, 101
duration of, 101–102
evaluation of, 97–99
initial, factors contributing to selection of, 99–101
monotherapy *vs.* combination therapy, 101
optimal regimen of, 102

HSCT. See *Hematopoietic stem cell transplantation (HSCT).*

Human immunodeficiency virus (HIV) infection, tuberculosis and. See *Tuberculosis, HIV-related.*

Hyaline Hyphomyetes, in transplant recipients, 676–678

Hyperbaric environments, pulmonary function effects of, 486–491

Hyperoxia, effects on lung function during diving, 356–357

Hypertension
at terrestrial altitude, 502
portopulmonary, **591–595.** See also *Portopulmonary hypertension.*
pulmonary. See *Pulmonary hypertension.*

Hyperventilation
excessive, apnea diving and, 387
exercise, in healthy untrained normal subjects, 439–440

Hypobaric exposures, pulmonary function effects of, 491

Hypoxemia, arterial, exercise-induced, 460–463. See also *Exercise-induced arterial hypoxemia (EIAH).*

Hypoxia, chronic, high-altitude pulmonary illness due to, 396

Hypoxia inhalation test, at high altitude, 496–497

Hypoxic pulmonary hypertension
altered, animal models of, 401
animal models of, 401

I

Idiopathic pneumonia syndrome, after HSCT, 561–563

IL. See *Interleukin(s).*

Immunity
adaptive, pneumonia in SOT recipients and, 114
during ALI, altered, 106–107
during mechanical ventilation, altered, 106–107

Immunoglobulin receptors, in genetic susceptibility to pneumonia, 31

Immunology, of *Streptococcus pneumoniae,* 124

Immunostimulation, in sepsis, 6

Immunosuppression
as factor in delayed resolution of pneumonia, 147–148
reduction of, for PTLD, 638–639

Immunosuppressive agents, for pneumonia in SOT recipients, 114–115

Immunotherapy
Aspergillus pulmonary infections in transplant recipients, 668
cellular, for PTLD, 640–641

Infection(s). See also specific infection, e.g., *Bacterial infection.*
experimental lung injury and, 105–106
lung, factors predisposing to, **11–17**
systemic diffusion of, mechanical ventilation effects on, 106
unusual, nonresolving pneumonia and, 149–150

Inflammation, systemic, mechanical ventilation effects on, 106

Influenza, 128–131
disease burden of, 128
vaccine for
clinical effectiveness of, 128–129
composition of, 128
future directions in, 131
immunogenicity of, 128
LAIV, 130–131
recommendations for, 129–130
safety of, 130

Influenza virus, in transplant recipients, 713

Inhaled aerosols, in microgravity studies, 432

Insulin therapy, for CAP-related sepsis, 26

Intensive care unit (ICU), admission to, by CAP patients, criteria for, 66–67

Interferon gamma signaling pathway, in genetic susceptibility to tuberculosis, 237–238

Interleukin(s) (IL)
IL-1α, in genetic susceptibility to pneumonia, 32–33
IL-1β, in genetic susceptibility to pneumonia, 32–33

IL-6, in genetic susceptibility to pneumonia, 33
IL-10, in genetic susceptibility to pneumonia, 33–34

Interleukin-1 receptor antagonist, in genetic susceptibility to pneumonia, 33

International Space Station, 416

Interstitial pulmonary edema, 463–464

Intrapulmonary arteriovenous shunting, exercise tolerance in persons with, 444–445

Intra-thoracic airway, limitations of, respiratory system response to exercise and, 448–453

Isoniazid
for active tuberculosis, 275
for latent *Mycobacterium tuberculosis* infection, 316–319
rifampin with, for latent *Mycobacterium tuberculosis* infection, 320–321

K

Kidney transplantation, 534–536
CMV infections after, 697
noninfectious pulmonary complications of, **623–629**

Klebsiella pneumoniae, VAP due to, mechanisms of resistance of, 77–78

L

LAIV. See *Live attenuated influenza vaccine (LAIV).*

Large-sequence polymorphisms, in *Mycobacterium tuberculosis* complex study, 210

Lectin, mannose-binding, in genetic susceptibility to pneumonia, 31

Legionella pneumonia, in solid organ transplant recipients, 649–651

Legionella sp.
in pneumonia resolution, 145–146
L. pneumophila
CAP due to, 51
VAP due to, 90

Line probe assays, in pulmonary tuberculosis diagnosis, 261

Live attenuated influenza vaccine (LAIV), for influenza, 130–131

Liver transplantation, 532–534
CMV infections after, 697
for hepatopulmonary syndrome, 587–591. See also *Hepatopulmonary syndrome.*
for portopulmonary hypertension, **591–595.** See also *Portopulmonary hypertension.*
noninfectious pulmonary complications of, **623–629**

LL3858, for tuberculosis, 335

Lower airways, colonization of, in pneumonia, 41

Luciferase reporter phages, in pulmonary tuberculosis diagnosis, 262

Lung(s)
at maximal exercise, **459–468**
diving effects on, long-term, 372–373
gas exchange in, in high-altitude environment, limitations of, 410–413
in space, **415–438**
mechanical ventilation effects on, 106

Lung cancer, after lung transplantation, 618

Lung disease(s), chronic, after HSCT, **571–586.** See also *Hematopoietic stem cell transplantation (HSCT), chronic lung disease after.*

Lung function, during diving, physical and physiological factors affecting, 356–358

Lung infection
bacterial, anti-inflammatory therapy in, 4–5
factors predisposing to, **11–17**
environmental factors in, 13–16
pulmonary defense mechanisms in, normal, 11–12
pulmonary host defenses in, **11–17**
systemic response to, **1–9.** See also *Pneumonia(s), systemic inflammatory response in.*

Lung parenchyma, age-associated changes in, 472

Lung transplant recipients, bronchiolitis obliterans syndrome in, pneumonia with, 649

Lung transplantation, 536–538
allograft rejection after, **599–612**
acute rejection, 603–606
immunopathogenesis of, 600–601
bronchiolitis obliterans syndrome due to, 606–608
hyperacute rejection, 599–600
induction immunosuppression for, 601–602
maintenance immunosuppression for, 602–603
CMV infections after, 696
noninfectious pulmonary complications after, **613–622**

anastomotic complications, 616–617
drug toxicity, 618–619
exercise limitation, 619
lung cancer, 618
native lung hyperinflation, 615–616
PGD, 613–614
phrenic nerve injury, 617
pleural complications, 617–618

Lung volumes
chest wall mechanics and, 417–420
in older persons, 473–474

Lung water, diffusing capacity and, in microgravity studies, 425

Lymphotoxin-α, in genetic susceptibility to pneumonia, 32

M

Macrolide(s), for tuberculosis, 335–336

Macrolide resistance, CAP due to, 59
clinical significance of, 60

Mannan-binding lectin (MBL), in genetic susceptibility to tuberculosis, 238

Mannose-binding lectin, in genetic susceptibility to pneumonia, 31

Maximal oxygen consumption, in older persons, 478–479

Maximizing gas exchange efficiency, during exercise, in healthy untrained normal subjects, 440–441

Maximum expiratory flows, in microgravity studies, 419–420

MBL. See *Mannan-binding lectin (MBL).*

Mechanical ventilation
altered immunity during, 106–107
lung effects of, 106
shortening of time of, in hospital-acquired pneumonia prevention, 135–136
systemic diffusion of infection effects of, 106
systemic inflammation effects of, 106

Metastatic pulmonary calcification, after transplantation, 625–626

Microgravity
analogs of, 417
making measurements in, 415–416
studies in, 417–434
cardiac output, 423–424
diffusing capacity and lung water, 425
exercise, 429
extravehicular activity, 433–434
functional residual capacity, 417–418
inhaled aerosols, 432
lung volumes and chest wall mechanics, 417–420
maximum expiratory flows, 419–420
pulmonary gas exchange, 427–428
pulmonary perfusion, 425–427
pulmonary ventilation, 420–423
residual volume, 418–419
shape and movement of chest wall, 420
sleep, 431–432
ventilation-perfusion ratio, 427–428
ventilatory control, 429–431
vital capacity, 417–418

MODS. See *Multiple organ dysfunction syndrome (MODS).*

Molecular beacons, in pulmonary tuberculosis diagnosis, 261

Moraxella catarrhalis, CAP due to, 49–50

Mosaic attenuation and air trapping, after transplantation, 552–553

Mountain sickness
acute, 397
chronic, 396
subacute, 396

Moxifloxacin, for tuberculosis, 331–333

Multiple organ dysfunction syndrome (MODS), defined, 20

Mycobacteria, nontuberculous
in HSCT recipients, 656
in solid organ transplant recipients, 653–654

Mycobacterial infections, in HSCT recipients, 656

Mycobacterial pneumonia
HIV/AIDS and, 52–53
in transplant recipients, **647–659.** See also *Solid organ transplant recipients, bacterial and mycobacterial pneumonia in.*

Mycobacterium tuberculosis
dissemination of, 226
geographic distribution of, 226
origin and evolution of, **207–216**

Mycobacterium tuberculosis complex
characteristics of, 207
deletions from, 212–214
genetic resources in study of, 207–210
fingerprinting patterns, 208

large-sequence polymorphisms, 210
sequenced genomes, 208
single-nucleotide polymorphisms, 208–210
origin and evolution of
chronologic, 211–212
ecologic, 211–212
genomic deletions and, 210–211
geographic, 211–212

Mycobacterium tuberculosis infection, latent
diagnosis of, 223
treatment of, **313–326**
challenges of, 322–323
difficulties with, 322–323
implementation-related issues in, 323
importance of, 314
in children, 322
in contacts of persons with drug-resistant tuberculosis, 322
in special situations, 322
indications for, 313–314
isoniazid in, 316–319
with rifampin, 320–320
monitoring for toxicity in, 323
prospects for improvements in, 323
regimens in, 314–316
rifampin in, 321
with pyrazinamide, 319–320
TNF-α antagonists and, 322
treatment completion rates in, 322–323
treatment initiation problems in, 322

Mycoplasma sp.
in pneumonia resolution, 146
M. pneumoniae. CAP due to, 50–51

Mycosis(es), endemic, in transplant recipients, 676, 679–680

N

Nasal colonization, in pneumonia, 39

National tuberculosis surveillance system, 184

Native lung hyperinflation, after lung transplantation, 615–616

Natural resistance–associated macrophage protein, in genetic susceptibility to tuberculosis, 235–237

Neoplasm(s), pulmonary, after transplantation, 626–627

Neurologic disorders, at terrestrial altitude, 502–503

Newborn(s), tuberculosis in, 302–303

NIPPV. See *Noninvasive positive-pressure ventilation (NIPPV)*.

Nitrogen narcosis, apnea diving and, 387–389

Nitroimidazopyran(s) (PA-824), for tuberculosis, 333–335

Nocardia infections
in HSCT recipients, 655
in solid organ transplant recipients, 651

Nodule(s), after transplantation, 553–558

Non-*Aspergillus* fungal pneumonia, in transplant recipients, **1–16.** See also *Fungal pneumonia, non-Aspergillus, in transplant recipients.*

Non-*Aspergillus* fungi, types of, 675–681

Nonfermentative gram-negative bacteria, VAP due to, 87–90

Noninvasive positive-pressure ventilation (NIPPV), in hospital-acquired pneumonia prevention, 135

Nonresolving pneumonia, **143–158.** See also *Pneumonia(s), nonresolving.*

Nontuberculous mycobacteria
in HSCT recipients, 656
in solid organ transplant recipients, 653–654

Nosocomial pneumonia, resolution of, patterns of, 144–145

Nucleic acid amplification assays, in pulmonary tuberculosis diagnosis, 258–260

O

OPC-67683, for tuberculosis, 335

Oropharyngeal aspiration, in pneumonia, 40

Oropharyngeal colonization, in pneumonia, 40

Oxacillin
Staphylococcus aureus resistant to, VAP due to, 92
Staphylococcus aureus sensitive to, VAP due to, 91–92

Oxazolidinones, for tuberculosis

Oxygen consumption, maximal, in older persons, 478–479

Oxygen prescription, at high altitude, 498–499

P

PA-284, for tuberculosis, 333–335

Paecilomyces sp., in transplant recipients, 676, 677

Pancreas transplantation, 538–540

Paracoccidioides brasiliensis, in transplant recipients, 676, 680

Parainfluenza virus, in transplant recipients, 712–713

Parenchyma, lung, age-associated changes in, 472

Patent foramen ovale, in divers, 491

PCP. See *Pneumocystis pneumonia (PCP).*

Peak expiratory flow, in older persons, 475–476

Penicillin-resistant *Streptococcus pneumoniae* (PRSP), 57
clinical significance of, 60

Penicillum sp.
in transplant recipients, 676, 678
P. marneffei, in transplant recipients, 676, 680

Periengraftment respiratory distress syndrome, after HSCT, 563–564

Periodic breathing during sleep, at terrestrial altitude, 500

Peripheral airways, age-associated changes in, 472

PGD. See *Primary graft dysfunction (PGD).*

Phage(s), lucifer reporter, in pulmonary tuberculosis diagnosis, 262

Phage amplification, in pulmonary tuberculosis diagnosis, 261–262

Phrenic nerve injury, after lung transplantation, 617

Pleural complications, after lung transplantation, 617–618

Pleural effusions, after transplantation, 625

Pneumococcus sp., in pneumonia resolution, 145

Pneumocystis pneumonia (PCP), in transplant recipients, 676, 681

Pneumonia(s). See also specific types, e.g., *Hospital-acquired pneumonia.*
aerobic gram-negative, CAP due to, 50
anaerobic bacterial, CAP due to, 50
artificial airway colonization in, 41–42
bacterial
HIV/AIDS and, 51–52
in transplant recipients, **647–659.** See also *Solid organ transplant recipients, bacterial and mycobacterial pneumonia in.*
bronchiolitis obliterans organizing, after HSCT, 576–577
CMV, in transplant recipients, **691–705.** See also *Cytomegalovirus (CMV) pneumonia, in transplant recipients.*
colonization in, infection and, relationship between, 42
community-acquired. See *Community-acquired pneumonia (CAP).*
in HSCT recipients, 654–655
in solid organ transplant recipients, 648–649
fungal. See *Fungal pneumonia.*
HIV/AIDS and, 53
gastric aspiration in, 40
gastric colonization in, 40
genetic susceptibility to, **29–38**
ACE in, 34
antigen recognition pathways in, 30–31
anti-inflammatory cytokines in, 33–34
CD14 in, 30–31
coagulation system genes in, 34–35
effector mechanisms in, 34–35
heat shock proteins in, 33
IL-1α in, 32–33
IL-1β in, 32–33
IL-1 receptor antagonist in, 33
IL-6 in, 33
IL-10 in, 33–34
immunoglobulin receptors in, 31
mannose-binding lectin in, 31
proinflammatory cytokines in, 31–33
surfactant proteins in, 34
toll-like receptors in, 31
tumor necrosis factor-α in, 31–32
genetic variability and, potential sites of, 29–30
hospital-acquired, **97–104.** See also *Hospital-acquired pneumonia.*
in HSCT recipients, 654–655
in solid organ transplant recipients, 648
in SOT recipients, **113–121.** See *Solid organ transplant (SOT) recipients, pneumonia in.*
Legionella, in solid organ transplant recipients, 649–651
lower airway colonization in, 41
mycobacterial
HIV/AIDS and, 52–53
in transplant recipients, **647–659.** See also *Solid organ transplant recipients, bacterial and mycobacterial pneumonia in.*
nasal colonization in, 39
nonresolving, **143–158.** See also *Pneumonia(s), resolution of.*
causes of, noninfectious, 150–151
described, 143–144

diagnostic evaluation of, 151–155
unusual infections and, 149–150
nosocomial, resolution of, patterns of, 144–145
oropharyngeal aspiration in, 40
oropharyngeal colonization in, 40
pathophysiology of, **39–46**
Pneumocystis, in transplant recipients, 676, 681
prevention of, **123–134.** See also *Vaccine(s).*
resolution of, 144
antimicrobials in, limitations of, 148–149
delayed, risk factors for, 147–148
in CAP, 144
pathogens in, 145–147
Chlamydia sp., 146
gram-negative bacilli, 146
Haemophilus sp., 145
Legionella sp., 145–146
Mycoplasma sp., 146
Pneumococcus sp., 145
Staphylococcus sp., 146–147
patterns of, 2–3
in nosocomial pneumonia, 144–145
sinusitis and, relationship between, 42–43
systemic inflammatory response in
assessment of, clinical utility of, 4
effect on lung innate and acquired immunity, 5–6
nature and magnitude of
host factors modulating, 3–4
microbial factors modulating, 2–3
ventilator associated. See *Ventilator-associated pneumonia (VAP).*
viral, in transplant recipients, **707–720.** See also *Viral pneumonias, in transplant recipients.*

Pneumonitis, radiation, after HSCT, 561

Pneumothorax
at high altitude, 499
in divers, 490

Polymorphism(s)
large-sequence, in *Mycobacterium tuberculosis* complex study, 210
single-nucleotide, in *Mycobacterium tuberculosis* complex study, 208–210

Portopulmonary hypertension, **591–595**
clinical presentation of, 591
defined, 591
diagnostic criteria for, 591–592
liver transplantation for
clinical course of, 594–595
intraoperative concerns, 594
natural history of, 593
pathophysiology of, 593
pretransplantation issues in, 593–594
screening for, 592–593

Post-transplant lymphoproliferative disorder (PTLD), **631–645**
classification of, 632–633
diagnosis of, 634
in HSCT recipients, 636–638
in solid organ transplant recipients, 635–636
pathophysiology of, 631–632
prevention of, 638–641
staging of, 634
surveillance of, 638
treatment of, 638–641
anti–B-cell antibodies in, 640
antiviral therapy in, 638
cellular immunotherapy in, 640–641
cytokines in, 639
cytotoxic chemotherapy in, 639–640
local therapy in, 639
reduction of immunosuppression in, 638–639

Primary graft dysfunction (PGD), after lung transplantation, 613–614

Proinflammatory cytokines, in genetic susceptibility to pneumonia, 31–33

Protein(s)
heat shock, in genetic susceptibility to pneumonia, 33
surfactant, in genetic susceptibility to pneumonia, 34

PRSP. See *Penicillin-resistant Streptococcus pneumoniae (PRSP).*

Pseudomonas aeruginosa, VAP due to, 87–89
mechanisms of resistance of, 76–77

PTLD. See *Post-transplant lymphoproliferative disorder (PTLD).*

Pulmonary calcification, metastatic, after transplantation, 625–626

Pulmonary capillary stress failure, 464–465
exercise and, 465

Pulmonary cytolytic thrombi, after HSCT, 578–579

Pulmonary disease, high-altitude–related, **395–404.** See also *High-altitude–related pulmonary disease.*

Pulmonary edema
diving while breathing compressed gas and, 368–369
interstitial, 463–464

Pulmonary embolism, at high altitude, 499

Pulmonary function
abnormalities of
after HSCT, 571–572
after transplantation, 627–628
at altitude, 500
exercise responses to, 460
extreme environments effects on, **485–507**

Pulmonary function tests, in older persons, 472–476
airway resistance and conductance, 476
flow-volume curves, 475–476
lung volumes, 473–474
peak expiratory flow, 475–476
respiratory muscle testing, 476
spirometry, 474–475

Pulmonary gas exchange, in microgravity studies, 427–428

Pulmonary hemorrhage, exercise-induced, 464–465

Pulmonary host defenses, in lung infection, **11–17**

Pulmonary hypertension
hypoxic
altered, animal models of, 401
animal models of, 401
in high-altitude residents, 396

Pulmonary infections, *Aspergillus*, in transplant recipients, **661–674.** See also *Aspergillus pulmonary infections, in transplant recipients.*

Pulmonary neoplasm, after transplantation, 626–627

Pulmonary perfusion, in microgravity studies, 425–427

Pulmonary vascular limitations, during exercise, 441–446

Pulmonary vascular response, to exercise in high-altitude pulmonary edema–prone persons, 445–446

Pulmonary vascular system, limitations of, exercise and, 453–454

Pulmonary veno-occlusive disease, after HSCT, 579–580

Pulmonary ventilation, in microgravity studies, 420–423

Pulse oximetry, at high altitude, 497–498

Pyrazinamide
for active tuberculosis, 277
rifampin with, for latent *Mycobacterium tuberculosis* infection, 319–320

Pyrrole (LL3858), for tuberculosis, 335

R

R207910, for tuberculosis, 333

Race, as factor in tuberculosis, 186

Radiation pneumonitis, after HSCT, 561

Red blood cell (RBC) transfusions, avoidance of, in hospital-acquired pneumonia prevention, 139

Residual volume, in microgravity studies, 418–419

Respiration, at high altitude, limits of, **405–414.** See also *High-altitude environment.*

Respiratory diseases, diving with, 370–371

Respiratory drive, disorders of, at terrestrial altitude, 500

Respiratory heat and water loss, effects on lung function during diving, 358

Respiratory mechanical loading, effects on lung function during diving, 357–358

Respiratory muscle function, age-associated changes in, 470–472

Respiratory muscle testing, in older persons, 476

Respiratory syncytial virus, in transplant recipients, 710–712

Respiratory system, aging effects on, **469–483**
carbon monoxide transfer factor, 477
chest wall changes, 469
gas exchange, 476–477
lung parenchyma, 472
maximal oxygen consumption, 478–479
peripheral airways, 472
pulmonary function tests related to, 472–476
regulation of breathing, 477–478
respiratory muscle function, 470–472
structural changes, 469–472
ventilatory response to exercise, 478–479

Respiratory virus(es), in transplant recipients, 715–716

Respiratory virus infection, community-acquired, prevention of, 716–718

Rhinovirus, in transplant recipients, 715–716

Rifampin
for latent *Mycobacterium tuberculosis* infection, 321
isoniazid with, for latent *Mycobacterium tuberculosis* infection, 320–321
pyrazinamide with, for latent *Mycobacterium tuberculosis* infection, 319–320

Rifamycin(s), for active tuberculosis, 275–276

Rifapentine, for tuberculosis, 328–331

S

Scedosporium sp., in transplant recipients, 676–677

Scopulariopsis sp., in transplant recipients, 676, 677–678

Sepsis
  CAP and, **19–28.** See also *Community-acquired pneumonia (CAP), sepsis due to.*
  defined, 19–20
  immunostimulation in, 6
  severe, defined, 19

Septic shock, defined, 20

Severe sepsis, defined, 19

Shock, septic, defined, 20

Shunt(s), EIAH and, 462

Shunting, in healthy untrained normal subjects, 441–444

Single-nucleotide polymorphisms, in *Mycobacterium tuberculosis* complex study, 208–210

Sinusitis, pneumonia and, relationship between, 42–43

SIRS. See *Systemic inflammatory response syndrome (SIRS).*

Sleep
  in microgravity studies, 431–432
  periodic breathing during, at terrestrial altitude, 500

Sleep-disordered breathing, at terrestrial altitude, 500

Smoking, in divers, 490

Solid organ transplant recipients, **529–543, 647–659**
  Aspergillus pulmonary infections in, 663
  bronchiolitis obliterans syndrome with pneumonia in, 649
  community-acquired pneumonia in, 648–649
  described, 648
  hospital-acquired pneumonia in, 648
  host defenses impairment in, 113–115
  Legionella pneumonia in, 649–651
  mycobacterial infections in, 651–654
  Nocardia infections in, 651
  nontuberculous mycobacteria in, 653–654
  pneumonia in, **113–121**
    evaluation of, 118–120
    immunosuppressive agents in, effects of, 114–115
    innate and adaptive immunity and, 114
    pathogens in, time line for, 116–118
    trends for, 115–116
  PTLD in, 635–636
  tuberculosis in, 651–653

Space, lung in, **415–438**

Space environment, 415–417

Space flight, early, 417

Space Shuttle, 416

Spirometry, in older persons, 474–475

Sputum, in pulmonary tuberculosis diagnosis, 255–256

SQ109, for tuberculosis, 336–338

Staphylococcus sp.
  in pneumonia resolution, 146–147
  S. aureus
    CAP due to, 50
    oxacillin-resistant, VAP due to, 92
    oxacillin-sensitive, VAP due to, 92
    VAP due to, mechanisms of resistance of, 75–76

Stenotrophomonas maltophilia, VAP due to, 90

Streptococcus sp.
  S. pneumoniae
    CAP due to, 47–48
    disease burden of, 123–124
    host defense against, 124
    immunogenicity of, 124
    immunology of, 124
    penicillin-resistant, 57
    vaccine for, 123–128
      clinical effectiveness of, 124–126
      history of, 123–124
      recommendations for, 126–128
  VAP due to, 92

Stress, decompression, effects on lung function during diving, 357

Subacute mountain sickness, 396

Surfactant proteins, in genetic susceptibility to pneumonia, 34

Systemic inflammation, mechanical ventilation effects on, 106

Systemic inflammatory response syndrome (SIRS), defined, 19

T

Terrestrial altitude, pulmonary function effects of, 499–503

Thrombus(i), pulmonary cytolitic, after HSCT, 578–579

TNF-α antagonists. See *Tumor necrosis factor-α (TNF-α) antagonists.*

Toll-like receptors, in genetic susceptibility to pneumonia, 31

Tracheobronchitis, in transplant recipients, treatment of, 668

Transplant recipients
- *Aspergillus* pulmonary infections in, **661–674.** See also *Aspergillus pulmonary infections, in transplant recipients.*
- CMV pneumonia in, **691–705.** See also *Cytomegalovirus (CMV) pneumonia, in transplant recipients.*
- coronavirus in, 715–716
- herpes viruses in, 715–716
- non-*Aspergillus* fungal pneumonia in, **675–690.** See also *Fungal pneumonia, non-Aspergillus, in transplant recipients.*
- rhiovirus in, 715–716
- viral pneumonias in, **707–720.** See also *Viral pneumonias, in transplant recipients.*

Transplantation. See also specific types, e.g., *Heart transplantation.*
- pulmonary complications of, radiographic considerations in, **546–561**
  - airspace consolidation, 546–551
  - ground-glass opacity, 551–552
  - mosaic attenuation and air trapping, 552–553
  - nodules, 553–558
- solid organ, **529–543.** See also *Solid organ transplant recipients.*

Travel, air, pulmonary function effects of, 493–499

Trichoderma sp., in transplant recipients, 676, 677

Trichosporon sp., in transplant recipients, 676, 681

Tuberculin skin test
- bacille Calmette-Guerin vaccination effects on, 306
- in active tuberculosis diagnosis, 255
- in latent tuberculosis diagnosis, 248–251
- in latent tuberculosis in children, 305–306

Tuberculosis
- active
  - diagnosis of, tests in, 254–255
  - treatment of, **273–282**
    - aminoglycosides in, 277
    - antimycobacterial agents in, pharmacology and toxicity of, 274–277
    - chemotherapy in, axioms of, 273–274
    - ethambutol in, 276
    - fluoroquinolones in, 276–277
    - guidelines in, 277–280
    - in special situations, 279–280
    - isoniazid in, 275
    - pyrazinamide in, 277
    - rifamycins in, 275–276
- control of, 214
- diagnosis of, **247–271**
  - rapid detection of drug resistance in, 261–262
- drug-resistant, 175–176
  - contacts of persons with, latent *Mycobacterium tuberculosis* infection treatment in, 322
  - in U.S., epidemiology of, 189–190
- genetic susceptibility to, **233–246**
  - 1,25-dihydroxyvitamin D_3 and, 238
  - HLA-DR2 and, 238
  - host genetics in, 234–235
    - identification of, 235
  - interferon gamma signaling pathway and, 237–238
  - MBL and, 238
  - natural resistance–associated macrophage protein and, 235–237
- global epidemic of
  - control of
    - acceleration in progress of, 179–180
    - DOTS strategy in, **197–205.** See also *Directly observed treatment, short course (DOTS) strategy, for controlling global tuberculosis epidemic.*
    - status of, 178–179
  - deaths due to, 170–171, 175
  - epidemiology of, **167–182**
  - new cases, 176–178
  - prevalence of, 170–171, 172–174
  - review of, 167–178
- HIV-related, 171–172, 190–191
  - DOTS strategy in control of, 201–202
  - treatment of
    - adherence to, 287
    - antiretroviral therapy with, 286–292
    - drug–drug interactions in, 288
    - immune reconstitution inflammatory events in, 289–290

issues in, **283–294**
optimal duration of therapy in, 284–286
overlapping adverse event profiles in, 287–288
recommendations in, 286, 292
in children, **295–312.** See also *Children, tuberculosis in.*
in HSCT recipients, 656
in solid organ transplant recipients, 651–653
in U.S.
elimination of, 192
epidemiology of, **183–195**
age and, 186
foreign-born persons and, 186–189
historical background of, 183–184
post-resurgence, 185–192
race/ethnicity factors, 186
resurgence, 184–185
latent, diagnosis of
beyond tuberculin skin test in, 251–254
tests in, 248–254
tuberculin skin test in, 248–251
multi-drug resistant, global epidemic of, control of, DOTS strategy in, 200–201
new tools for, 191–192
pathogenesis of
drug resistance effects on, 222
lessons learned regarding, 219–226
pulmonary
diagnosis of
cultures in, 257–258
fiberoptic bronchoscopy in, 256–257
line probe assays in, 261
luciferase reporter phages in, 262
methods in, 255–260
molecular beacons in, 261
nucleic acid amplification assays in, 258–260
phage amplification in, 261–262
sputum in, 255–256
tuberculin skin test in, 255
in children, 299–300
transmission of
community epidemiology and, 224
contact investigations, 222–223
control of
genotyping methods in, 217–219
molecular epidemiology and, **217–231**
future of, 226
drug resistance effects on, 222
exogenous reinfection and, 220–222
infectiousness of patients and, 219–220
lessons learned regarding, 219–226
mixed infection and, 220–222
outbreak investigations, 222–223
risk factors for clustering in, 224
treatment of
diarylquinolones (R207910) in, 333
dihydroimidazo-oxazoles (OPC-67683) in, 335
drug development for, 328
Global Alliance for, **341–347.** See also *Global Alliance for Tuberculosis Drug Development.*
drug(s) in
new, **327–340**
pipeline of, 333–338
macrolides in, 335–336
moxifloxacin in, 331–333
nitroimidazopyrans (PA-284) in, 333–335
oxazolidinones in, 336
pyrrole (LL3858) in, 335
rifapentine in, 328–331
SQ109 in, 336–338
widely spaced intermittent, 328–331

Tuberculosis control program, performance of, measurement of, 224–226

Tuberculosis disease, case definitions of, 303–305

Tuberculosis infection, latent, treatment of, **313–326.** See also *Mycobacterium tuberculosis infection, latent, treatment of.*

Tuberculosis/HIV coinfection, 190–191

Tumor necrosis factor-α (TNF-α), in genetic susceptibility to pneumonia, 31–32

Tumor necrosis factor-α (TNF-α) antagonists, latent *Mycobacterium tuberculosis* infection treatment and, 322

U

Upper airway, injury of, after HSCT, 561

V

Vaccination(s), bacille Calmette-Guerin, effect on tuberculin skin test, 306

Vaccine(s). See also specific type.
for influenza, 128–131
for *Streptococcus pneumoniae,* 123–128
in pneumonia prevention, **123–134.** See also specific vaccine, e.g., *Streptococcus pneumonia, vaccine for.*
hospital-acquired, 139

VAP. See *Ventilator-associated pneumonia (VAP).*

Venous thrombosis, deep, at high altitude, 499

Ventilation
alveolar, EIAH and, 463
exercise and, in older persons, 478
mechanical. See *Mechanical ventilation.*
pulmonary, in microgravity studies, 420–423

Ventilation-perfusion ratio, in microgravity studies, 427–428

Ventilation-perfusion ratio inequality, EIAH and, 462

Ventilator-associated pneumonia (VAP). See also *Hospital-acquired pneumonia.*
causes of, **87–95**
Acinetobacter baumannii, 89–90
aerobic gram-positive cocci, 91–92
anaerobes, 93
bacterial, mechanisms of resistance of, **75–79**
Acinebacter sp., 76–77
Enterobacter cloacae, 77–78
Klebsiella pneumoniae, 77–78
Pseudomonas aeruginosa, 76–77
Staphylococcus aureus, 75–76
enterobacteriaceae, 90
Haemophilus influenzae, 90–91
Legionella pneumophila, 90
nonfermentative gram-ncgative bacteria, 87–90
opportunistic pathogens, 93
Pseudomonas aeruginosa, 87–89
Staphylococcus aureus
oxacillin-resistant, 92
oxacillin-sensitive, 91–92
Stenotrophomonas maltophilia, 90
Streptococcus sp., 92
defined, 135
during ARDS, clinical studies of, 140
histologic characteristics of, 43–45
microbiologic diagnosis of, **81–86**
clinical pulmonary infection score in, 81–83
respiratory samples in, culture of, 83–85
serial information in, 85
prevention of, nonpharmacologic approaches in, 135–138

Ventilatory control, in microgravity studies, 429–431

Ventilatory demand, at high altitude, 406–407

Ventilatory response to exercise, in older persons, 478–479

Viral pneumonias, in transplant recipients, **707–720**
adenovirus, 714–715
diagnosis of, 708–709
epidemiology of, 707–708
general observations in, 707–709
influenza virus, 713
outcomes of, 709
parainfluenza virus, 712–713
respiratory syncytial virus, 710–712

Virus(es)
in transplant recipients
herpes viruses, 715–716
influenza virus, 713
parainfluenza virus, 712–713
respiratory syncytial virus, 710–712
respiratory, in transplant recipients, 715–716

Vital capacity, in microgravity studies, 417–418

Voriconazole, for *Aspergillus* pulmonary infections in transplant recipients, 667

Y

Yeast(s), in transplant recipients, 676, 680–681

Z

Zygomycete(s), in transplant recipients, 676, 678